Investors
Investor Relations
Corporate Profile
Prelude is a clinical-stage biopharmaceutical company designing and developing a pipeline of novel, orally bioavailable, small molecule therapies that target key drivers of cancer cell growth, survival and resistance.
Stock Information
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Investor Tools